Journals / Tüberküloz ve Toraks / 2020 / Cilt: 68 - Sayı: 2

Asthma and COVID-19: What do we know?

Astım ve COVID-19: Ne biliyoruz?

Pages
141–147
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aimed to summarize theapproach to patients with asthma during the pandemic and to make recommendations concerning it.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are limited data about the coexistence of asthma and the Coronavirusdisease-2019 (COVID-19).
📊
Key Findings & Data:The COVID-19 pandemic is a new disease for thewhole world.
💡
Conclusion & Impact:In this review, we aimed to summarize theapproach to patients with asthma during the pandemic and to make recommendations concerning it.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

There are limited data about the coexistence of asthma and the Coronavirusdisease-2019 (COVID-19). The COVID-19 pandemic is a new disease for thewhole world. In this study, we aimed to examine the published case serieswith the COVID-19 and asthma coexistence, by reviewing existing studies andother publications. We discussed the suggestions of guidelines such as TheGlobal Initiative for Asthma (GINA), The National Institute for Health andCare Excellence (NICE), and the Canadian Respiratory Guideline about themanagement of asthma during the COVID-19 pandemic and the experiencesof different countries. We analyzed the publications, reports, and expert opinions about asthma and COVID-19, that were released and expressed from theonset of the disease in Wuhan. In this review, we aimed to summarize theapproach to patients with asthma during the pandemic and to make recommendations concerning it.

Özet

Astım ve koronavirüs hastalığı-2019 (COVID-19) birlikteliği hakkında sınırlı sayıda veri bulumaktadır. COVID-19 pandemisi tüm dünyanın yeni tecrübe ettiği bir hastalıktır. Biz burada, astım ve COVID-19 ile ilgili yayınlanmış olan olgu serilerini ve varsa yapılmış çalışmaları ve diğer yazıları irdelemeye çalıştık. “The Global Initiative for Asthma (GINA)”, “The National Institute for Health and Care Excellence (NICE)” ve “Canadian Respiratory Guideline” gibi rehberlerin COVID-19 pandemisi sırasındaki astım yönetimi konusundaki önerilerini ve farklı ülkelerdeki deneyimleri ele aldık. Hastalığın Wuhan’da ilk ortaya çıkışından bu güne kadar astım ve COVID-19 hakkında bildirilen yayınları, raporları ve uzman görüşlerini inceledik. Bu yazıda pandemi sırasında astım hastalarına yaklaşımı özetlemeye ve önerileri sunmaya çalıştık.

🔖

Cite This Article

SARIOĞLU, N. (2022). Asthma and COVID-19: What do we know?. Tüberküloz ve Toraks, Cilt: 68 - Sayı: 2, 141–147. https://ajindex.com/articles/618357

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available from:https:// www.who.int/dg/ speeches/detail/ who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19---11-march-2020, Accessed 15th Mar 2020 2. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) situation summary Available from: https://www.cdc.gov/coronavirus/2019-ncov/ index.html, Accessed 15th Mar 2020 3. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy 2020. doi: 10.1111/ all.14238. 4. Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019
  2. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020 pii: S0091- 6749(20)30495-4. 6. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. Allergy 2020. doi: 10.1111/all.14289. 7. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020
  3. 55(5). pii: 2000547. doi: 10.1183/13993003.00547- 2020 8. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020
  4. 69(15):458- 64. doi: 10.15585/ mmwr.mm6915e3. 9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, et l. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020. doi: 10.1001/ jama.2020.6775 10. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020
  5. 8(1):e35. eCollection 2020. 11. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. COVID- 19 SARS-CoV-2 preprints from medRxiv and bioRxiv 2020. doi: 10.1101/2020.05.06.20092999 12. Konopka KE, Wilson A, Myers JL. Postmortem